Evaluation of clinical efficacy of carbidopa/levodopa sustained-release capsules

Carbidopa/levodopa extended-release capsules (carbidopa and levodopa) are a combination drug used to treat Parkinson's disease and related symptoms. Parkinson's disease is a chronic neurodegenerative disease characterized by motor dysfunction such as resting tremor, muscle stiffness, and bradykinesia. In addition, the drug may also be used to treat Parkinson's syndrome caused by carbon monoxide poisoning or manganese poisoning. The combination of carbidopa and levodopa effectively relieves these symptoms and improves patients' quality of life by replenishing dopamine levels in the brain.

Carbidopa/The core mechanism of action of levodopa sustained-release capsules is to convert levodopa into dopamine to supplement the lack of dopamine in the brain, thereby improving the motor function of patients with Parkinson's disease. Clinical studies have shown that the drug can significantly reduce symptoms such as tremor, stiffness and bradykinesia, and improve patients' ability to carry out daily activities.

Compared with ordinary dosage forms, sustained-release capsules can provide a more stable blood concentration and reduce the occurrence of "switching phenomenon" (symptoms fluctuate between relief and exacerbation). This dosage form design makes the drug's efficacy more durable and significantly improves the patient's quality of life. The efficacy of long-term use of carbidopa/L-dopa sustained-release capsules is relatively stable, but some patients may experience decreased efficacy or movement disorders (such as dyskinesia). Therefore, the dosage needs to be adjusted regularly under the guidance of a doctor to ensure the safety and effectiveness of the drug.

Carbidopa/Levodopa sustained-release capsules were approved by the U.S. Food and Drug Administration (FDA) on August 7, 2024, and were officially launched in the United States. As a new sustained-release drug, its launch provides more treatment options for patients with Parkinson's disease. However, due to its short time on the market, pricing information is currently unclear. Patients in need can follow the FDA official website or relevant pharmaceutical news to get the latest updates. For patients who are in urgent need of medication, it is recommended to contact regular overseas medical consulting institutions to obtain professional medication guidance and purchase channels.

Reference link: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217186s000lbl.pdf